BioSpace News Archive

Moderna, Inc. announced it was ranked one of the top employers in the global biopharmaceutical industry by Science and Science Careers’ 2022 Top Employers Survey for the eighth consecutive year.

Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that it will be presenting new preclinical data for its CD38-targeted Flex-NK™ cell engager antibodies at the American Society of Hematology’s 64th Annual Meeting.

 Building reinforces the company’s sustainable growth strategy  New logistic infrastructure extends storage capacity of packaging materials  Further investments are planned across the company

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2022 financial results and provide a corporate update on Thursday, November 10, 2022.

Monopar Therapeutics Inc. will be presenting clinical data on camsirubicin and preclinical data on MNPR-202 in November and December, and is planning to report out the interim go/no-go analysis for its Validive Phase 2b/3 VOICE trial in Q1 2023.

Sema4 (Nasdaq: SMFR), a health insights company, today announced updated research showing the clear benefits of rapid whole genome sequencing (rWGS) to diagnose critically ill newborn in the neonatal intensive care unit (NICU).

Myeloid Therapeutics, Inc. (“Myeloid”), a clinical-stage mRNA-immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to MT-101 in patients with refractory or relapsed CD5+.

Arcadia Biosciences, Inc. today announced that it will release its financial and business results for the third quarter and first nine months of 2022 after market close on November 10, 2022.

Phoenix Molecular Designs, a clinical-stage biopharmaceutical company dedicated to developing precise cancer therapeutics, announced the appointment of Martin S. Olivo, MD, MSc to its advisory board.

Triumvira Immunologics today announced that it will present data from its ongoing clinical and preclinical programs at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held Nov. 10-12, 2022.